← Back to Search

Chemotherapy

CLAG Regimen with Gleevec® for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Led By Rami Komrokji, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 20 Other Conditions
No Placebo-Only Group

Summary

The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate (ORR)
Secondary study objectives
Median Overall Survival (OS)
Median Progression Free Survival (PFS)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CLAG Regimen with Gleevec®Experimental Treatment2 Interventions
Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imatinib
FDA approved
Filgrastim
FDA approved

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
563 Previous Clinical Trials
144,833 Total Patients Enrolled
NovartisIndustry Sponsor
1,638 Previous Clinical Trials
2,774,165 Total Patients Enrolled
Rami Komrokji, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute
4 Previous Clinical Trials
119 Total Patients Enrolled
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top